Skip to content
Medical Health Aged Care

Patient subsidies for GP-performed ECGs must be restored

Royal Australian College of GPs 2 mins read

The Royal Australia College of GPs (RACGP) has called for the restoration of patient Medicare rebates for GPs interpreting electrocardiograms (ECGs). 

In its submission to a review of changes to ECG Medicare Benefits Schedule (MBS) items, the RACGP called for revised MBS items to be introduced without delay. 

An ECG records the electrical signals in the heart and is a common test used to quickly detect heart problems and monitor heart health. 

RACGP Vice President Associate Professor Michael Clements said: “The RACGP strongly opposed the removal of this subsidy for GP patients, which restricted certain ECG services to non-GP specialists and consultant physicians, with much higher costs for patients. 

“We are calling for funding to be returned without delay because it’s impacting patients’ access to affordable care, timely diagnosis and management of heart conditions. This risks people’s health getting worse. 

“Coronary heart disease is the leading cause of death in Australia. The Heart Foundation recently cited data showing preventive heart disease screening in general practice could prevent over 67,000 heart attacks, strokes, and heart related deaths over five years. We need to improve access to screening for cardiovascular diseases. 

“When GPs lost this subsidy for patient care, it resulted in a 33% reduction in ECG services from GPs and other medical professionals. This may save the government’s bottom line, but it’s risking the health of our community. We know the need for ECGs is increasing due to our demographics – an ageing population and increasing rates of chronic illness. 

“The reinstatement of MBS funding for GPs to provide both tracing and interpretation of ECG results is essential for the care of people experiencing or at risk of cardiac complications. Other specialists rely on the expertise of GPs to perform and interpret ECGs, such as before a patient starts stimulant medicines for ADHD treatment. 

“GPs are specialists and do the same eight years medical training as any other specialist doctor. We have the skills to conduct, interpret and report on ECGs. General practice is also the most cost-effective care for patients, our health system and taxpayers.  

“Reinstating patient rebates for their GP to provide both tracing and interpretation of ECGs will immediately improve access to care, as well as reduce costs for all Australians who need these services, at a time when we are still battling a cost-of-living crisis.” 

~ENDS 


About us:

The Royal Australian College of General Practitioners (RACGP) is the peak representative organisation for general practice, the backbone of Australia’s health system. We set the standards for general practice, facilitate lifelong learning for GPs, connect the general practice community, and advocate for better health and wellbeing for all Australians.

Visit www.racgp.org.au. To unsubscribe from RACGP media releases, click here.


Contact details:

John Ronan
Media Adviser

Ally Francis
Media Adviser

Stuart Winthrope
Media Officer

Contact: 03 8699 0992media@racgp.org.au

Follow us on Twitter: @RACGP and Facebook.

More from this category

  • Medical Health Aged Care
  • 31/10/2024
  • 17:55
Kyowa Kirin Co., Ltd.

Kyowa Kirin Announces Changes in Top Leadership Positions to Strengthen Operations as a Global Specialty Pharmaceutical Company

Masashi Miyamoto to be named Chairman and CEO Abdul Mullick to be named President and COO Changes designed to further deliver on company’s 2030…

  • Contains:
  • Medical Health Aged Care
  • 31/10/2024
  • 12:10
MannKind

First Site Initiated in Australia for MannKind’s Phase 3 Clinical Trial Evaluating Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

ICoN-1 study presentation planned November 1 at NTM Symposium AustraliaStudy is cleared by health authorities to proceed in Australia, U.S., Japan and South Korea, with Taiwan anticipated by end of year DANBURY, Conn., Oct. 30, 2024 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that it has initiated its first site for its Phase 3 clinical trial evaluating efficacy and safety of Clofazimine Inhalation Suspension for the treatment of nontuberculous mycobacterial (NTM) lung disease. The study,…

  • Business Company News, Medical Health Aged Care
  • 31/10/2024
  • 11:03
Firebrick Pharma

Agreement Signed to Market Nasodine to Healthcare Professionals in Singapore

Firebrick Pharmais pleased to announce that it has executed a Marketing Representation Agreement (the “Agreement”) with Singapore-based, Innorini, trading as Innorini Life Sciences (“Innorini”). The initial term of the Agreement is one year with the option to renew for subsequent one-year terms by mutual agreement. Under the Agreement, Innorini will undertake “Marketing Services” commencing 1 November 2024. The Marketing Services comprise sampling and promotion of Nasodine® Nasal Spray (“Nasodine”) to General Practitioners (“GPs”) and hospital-based doctors and pharmacists (collectively “HCPs”) in Singapore. In addition to building awareness and support of Nasodine by HCPs, Innorini will be expected to sell Nasodine…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.